IROKO. A RESPONSIBLE PARTNER
WITH GLOBAL REACH

Developing Innovative Ways to Feel Better

 

 

At Iroko, we believe it is possible to offer new options for responsible pain management. Medical and regulatory organizations have recommended the use of the lowest effective doses of NSAIDs for the shortest duration of time.

We are using innovative proprietary SoluMatrix Fine Particle Technology™ to develop new drug products based on existing NSAIDs to relieve pain at lower doses.

Guidance for Responsible Pain Management
In 2005, the FDA issued a public health advisory recommending the use of NSAIDs at the lowest effective dose for the shortest duration of time, consistent with patient treatment goals. These recommendations are particularly important, as the use of NSAIDs is on the rise. In 2012, there were more than 109 million prescriptions in the United States alone.

Small Particles That Are Advancing Analgesics
Iroko has developed the first lower dose NSAIDs using SoluMatrix Fine Particle Technology™. This technology produces NSAIDs as submicron particles that are approximately 20 times smaller than their original size. The reduction in particle size provides an increased surface area, leading to faster dissolution.

SoluMatrix Fine Particle Technology™ is a trademark of iCeutica Inc., and is licensed to Iroko for exclusive use in NSAIDs.